Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | ARF6 | P62330 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 3/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230451 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AMAPTTTR | |
| SCHEMBL29357766 | 0.84 | MEN1 (0.52) | MMP2ARF6ALDH1A1MEN1KMT2A | |
| SCHEMBL2678980 | 0.84 | L3MBTL1 (0.48) | MMP2ARF6ALDH1A1MEN1KMT2A | |
| SCHEMBL16097443 | 0.84 | MMP2 (0.43) | MMP2ARF6ALDH1A1MEN1KMT2A | |
| SCHEMBL20548070 | 0.83 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AMAPTHSPB1 | |
| SCHEMBL6150745 | 0.82 | MMP2 (0.42) | MMP2ARF6ALDH1A1MEN1KMT2A | |
| SCHEMBL10684702 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AMAPTHSPB1 | |
| SCHEMBL4423862 | 0.81 | MMP2 (0.53) | MMP2ALDH1A1KMT2AMAPT | |
| SCHEMBL8740500 | 0.81 | MMP2 (0.53) | MMP2ALDH1A1KMT2AMAPT | |
| SCHEMBL2387943 | 0.81 | MMP2 (0.53) | MMP2ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193291-A1 | METHOD FOR PRODUCING BLOCKPOYMERS BY MEANS OF LINKING BLOCKS BY A TRANSPEPTIDASE, AND BLOCK POLYMERS OBTAINED BY TRANSPEPTIDASE LINKING | FRAUNHOFER GES FORSCHUNG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-2049570-B1 | PURIFICATION OF A BIVALENTLY ACTIVE ANTIBODY USING A NON-CHROMATOGRAPHIC METHOD | HARVARD COLLEGE (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8124743-B2 | Purification of a bivalently active antibody using a non-chromatographic method | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090240040-A1 | PURIFICATION OF A BIVALENTLY ACTIVE ANTIBODY USING A NON-CHROMATOGRAPHIC METHOD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-24 | — | — | US | disclosed |
| EP-2049570-A2 | PURIFICATION OF A BIVALENTLY ACTIVE ANTIBODY USING A NON-CHROMATOGRAPHIC METHOD | President and Fellows of Harvard College (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007143121-A2 | PURIFICATION OF A BIVALENTLY ACTIVE ANTIBODY USING A NON-CHROMATOGRAPHIC METHOD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2003066096-A1 | POLYMERIC CONJUGATES FOR DELIVERY OF MHC-RECOGNIZED EPITOPES VIA PEPTIDE VACCINES | VAXIM, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20030049253-A1 | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines | VAXIM | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193291-A1 | METHOD FOR PRODUCING BLOCKPOYMERS BY MEANS OF LINKING BLOCKS BY A TRANSPEPTIDASE, AND BLOCK POLYMERS OBTAINED BY TRANSPEPTIDASE LINKING | RNPEP, DNPEP, ENPEP | MMP2 165/4885ARF6 2371/4885ALDH1A1 1889/4885 |
| US-20030049253-A1 | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines | MICA, CD44, CD74 | MMP2 765/4885ARF6 2882/4885ALDH1A1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.